Celgene Corporation

Signal Pharmaceuticals, Inc.

Rama Krishna Narla

Shuichan Xu

Antonia Lopez-Girona

Mark A Nagy

John J Sapienza

Patrick Papa

Lida R Tehrani

Jan Elsner

Jennifer Riggs

Roy Leonard Harris, Iii

Michael Pourdehnad

Maria Soraya Carrancio Anton

Tonia J Buchholz

Joshua Hansen

Timothy S Kercher

Matthew Daniel Correa

Heather K Raymon

Brandon Wade Whitefield

Kristen Mae Hege

Shailaja Kasibhatla

Stephen Norris

Sogole Bahmanyar

Evan J Horn

Christopher Mayne

Massimo Ammirante

Surendra Nayak

Dehua Huang

Paul E Erdman

Raj Kumar Raheja

Deborah Mortensen

Garrick Kenneth Packard

Veronique Plantevin-Krenitsky

Jingjing Zhao

John Frederick Boylan

Sophie Perrin-Ninkovic

Jason Parnes

Graziella I Shevlin

Rajesh Chopra

Branden Gingsee Lee

Tam Minh Tran

Virginia Heather Sharron Grant

Weiming Xu

Brandon Jeffy

Kimberly Elizabeth Fultz

Andrew Antony Calabrese

Dan Zhu

Sabita Sankar

Yuhong Ning

Dale Robinson

Loui Madakamutil

Ellen Filvaroff

Henry Ping Chang

Anjan Thakurta

Toshiya Tsuji

William Edward Pierceall

Adithi Mohan

Hon-Wah Man

Matthew David Alexander

Brian Edwin Cathers

Nanfei Zou

Lilly L Wong

Daniel W Pierce

Paula Alessandra Tavares-Greco

Xiaoling Lu

Courtney G Havens

Roy L Harris, Iii

Gerald D Artman, Iii

Virginia H Grant

Soraya Carrancio

James Carmichael

Joseph R Piccotti

Gordon L Bray

Paula A Tavares-greco

Veronique Plantevin-krenitsky

Jennifer R Riggs

Branden Lee

Sogoie Bahmanyar

Shuichan Su

Gerald D Iii Artman

Brandon David Jeffy

Graziella Shevlin

Fultz Kimberly

Madakamutil Loui

Provided herein are piperidine dione compounds having the following structure:

Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1/H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.

Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use

Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing hematological malignancies.

Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion

Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.

Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

Antiproliferative compounds and methods of use thereof

Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKC&#x3b2; inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1/H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.

Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Provided herein are piperidine dione compounds having the following structure: 

Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

Treatment of cancer with TOR kinase inhibitors

Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.

Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy

Growing community of inventors

San Diego, CA, United States of America

Rama Krishna Narla